MC 1101
Alternative Names: MC-1101; SB 04Latest Information Update: 23 Feb 2021
At a glance
- Originator Texas A&M University
- Developer Changhua Christian Hospital; MacuCLEAR; Mystic Pharmaceuticals; National Taiwan University Hospital
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dry age-related macular degeneration
Most Recent Events
- 23 Feb 2021 No development reported - Phase-II/III for Dry age-related macular degeneration in Taiwan (Ophthalmic)
- 23 Feb 2021 No development reported - Phase-II/III for Dry age-related macular degeneration in USA (Ophthalmic)
- 15 May 2018 Phase-II/III clinical trials in Dry age-related macular degeneration in Taiwan (Ophthalmic) before May 2018